Slide 1: Investor Presentation May 2024
Investor Presentation May 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.1
Slide 2: Legal Disclaimers
Legal Disclaimers ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate
Slide 3: Pipeline represents potential multi billion-dollar opportunities
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Pipeline represents potential multi billion-dollar opportunities DURAVYU™ (vorolanib intravitreal insert) – vorolanib, a selective and patented TKI in Durasert E™ First pivotal phase 3 trial in wet AMD on-track to initiate in 2H 2024 Positive
Slide 4: Durasert E Programs
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. wet AMD, wet age-related macular degeneration; EOP2, End of Phase 2; FPI, first patient in; NPDR, non-proliferative diabetic retinopathy; DME, diabetic macular edema; GA, geographic atrophy Durasert E™ Programs Indication Discovery Pre-Clin P
Slide 5: Durasert - Intravitreal Sustained-Release Drug Delivery
Safe, Sustained IVT Drug Delivery Delivered via a standard in-office IVT injection Continuous, stable release of drug Zero-order kinetics Durasert®: non-erodible Drug embedded within a bioerodible matrix covered with non-erodible polyimide shell: YUTIQ®1 ILUVIEN®1 RETISERT®2 VITRASERT®2 Durasert E™:
Slide 6: Vorolanib Brings a Potential New MOA to Treatment of VEGF-Mediated Retinal Diseases
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Sophie Bakri, M.D., et al. PLOS ONE, Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects, 2024. VEGF(R), vascular endothelial growth factor (re
Slide 7: DURAVYU: VEGF Receptor Binding Vorolanib in Bioerodible Durasert E
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Insert is ~1/5000 of vitreous volume Positive efficacy data in wet AMD from Phase 1 DAVIO and Phase 2 DAVIO 2 clinical trials Favorable safety profile with no ocular or systemic DURAVYU-related SAEs reported in ongoing Phase 2 clinical trials
Slide 8: Phase 2 DAVIO 2 Clinical Trial Topline Results in wet AMD
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 DAVIO 2 Clinical Trial Topline Results in wet AMD A NON-INFERIORITY TRIAL VERSUS AN AFLIBERCEPT CONTROL
Slide 9: The DAVIO 2 Clinical Trial in wet AMD
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. The DAVIO 2 Clinical Trial in wet AMD A non-inferiority trial evaluating two doses of DURAVYU against an aflibercept control as a potential 6-month maintenance therapy Design: Multi-center, randomized, double-masked trial in patients with pre
Slide 10: DAVIO 2 Trial Design: Randomized, Double-Masked, Aflibercept Controlled
DAVIO 2 Clinical Trial is Randomized, Double-Masked, Aflibercept Controlled* with a Single DURAVYU Treatment at Two Doses ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 DURAVYU 2mg low dose n=53 DURAVYU 3mg high dose n=54 Aflibercept
Slide 11: DAVIO 2 Patient Baseline Characteristics Well Balanced Across Arms
DAVIO 2 Patient Baseline Characteristics Well Balanced Across Arms ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Aflibercept 2mg q8W (n=54) DURAVYU 2mg (n=50) DURAVYU 3mg (n=52) Mean age, years (range) 75.9 (52-93) 76.4 (61-93) 75.4 (56-89) Female, % 53.7% 64.0% 67.3% Mean BCVA, ETDRS le
Slide 12: DAVIO 2 Met All Primary and Secondary Objectives
DURAVYU Phase 2 DAVIO 2 Clinical Trial in Wet AMD Met All Primary and Secondary Objectives ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. As of November 7, 2023 data cut PRELIMINARY DATA – PENDING FINAL ANALYSIS Endpoint Endpoint Achieved 2mg Arm 3mg Arm Primary: Non-inferior change in
Slide 13: DURAVYU Statistically Non-Inferior in Change in BCVA vs Aflibercept
DURAVYU 2mg -0.3* Mean Change in BCVA vs Aflibercept DURAVYU 3mg -0.4* ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. +0.9* +1.0* +1.3* DURAVYU was Statistically Non-Inferior in Change in BCVA Compared to the Aflibercept Control (95% CI) MEAN CHANGE IN BCVA FROM BASELINE *Blended week 28
Slide 14: 95% Confidence Intervals Showed Non-Inferiority for Primary Endpoint
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 95% Confidence Intervals Showed Statistical Non-Inferiority for Primary Endpoint with DURAVYU vs Aflibercept Control PRELIMINARY DATA – PENDING FINAL ANALYSIS BCVA units were ETDRS letters. BCVA, best-corrected visual acuity; CI, confidence i
Slide 15: DURAVYU Demonstrated a Favorable Safety Profile in DAVIO 2
DURAVYU Demonstrated a Favorable Safety Profile in the Phase 2 DAVIO 2 Clinical Trial1 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. SAE, serious adverse event; AE, adverse event; IVT, intravitreal injection PRELIMINARY DATA CUT– PENDING FINAL ANALYSIS 1- As of November 7, 2023 data cut
Slide 16: DURAVYU Continues to Show a Favorable Safety Profile Across Multiple Trials
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Data as of April 25, 2024 1-Data are preliminary pending study completion and final report. SAE, serious adverse event Summary: DAVIO (Phase 1): 17 patients treated DAVIO 2 (Phase 2)1: 102 patients treated PAVIA (Phase 2)1: 51 patients treate
Slide 17: Clinically Meaningful Reduction in Treatment Burden
Clinically Meaningful Reduction in Treatment Burden Supports DURAVYU as a Maintenance Treatment For Wet AMD ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Normalized PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU 2mg DURAVYU 3mg Mean number of injections week 8 through week 32 0.55 0.
Slide 18: Reduction in Treatment Burden vs. Aflibercept Control Arm
DURAVYU Demonstrated a Meaningful Reduction in Treatment Burden vs. the Aflibercept Control Arm ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS. DURAVYU 2mg DURAVYU 3mg Aflibercept 2mg q8W Mean number of injections week 8 through week 32 0.55 0.71
Slide 19: Clinically Meaningful Supplement-Free Rates
DURAVYU Demonstrated Clinically Meaningful Supplement-Free Rates with ≥83% of Eyes Receiving 0-1 Anti-VEGF Supplemental Injections ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *PRELIMINARY DATA – PENDING FINAL ANALYSIS Number of Supplemental Injections Six Months After DURAVYU Insert DU
Slide 20: Nearly Two-Thirds of Eyes Supplement-Free Up to Six Months
Nearly Two-Thirds of Eyes Treated with DURAVYU were Supplement-Free up to Six Months After a Single Injection ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *First visit patients are eligible to be rescued **Month 8 represents 6 months post DURAVYU injection PRELIMINARY DATA – PENDING FIN
Slide 21: 2mg Dose Reduced Treatment Burden by 89%
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU 2mg Dose Reduced Treatment Burden by 89% Compared to Prior 6 Months Injections in year prior and during the DAVIO 2 trial DURAVYU 3 mg (n = 52) DURAVYU 2 mg (n = 50) Anti-VEGF injection Aflibe
Slide 22: 3mg Dose Reduced Treatment Burden by 85%
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRELIMINARY DATA – PENDING FINAL ANALYSIS Injections in year prior and during DAVIO 2 trial DURAVYU 3 mg (n = 52) DURAVYU 2 mg (n = 50) Anti-VEGF injection Aflibercept loading dose Aflibercept + DURAVYU No injection Missed Visit Supplemental
Slide 23: Strong Anatomic Control with OCT Change Below 10 Microns
DURAVYU 2mg +9.7 Mean Change in CST vs Aflibercept DURAVYU 3mg +5.2 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. +10.6 um +15.1 um +5.4 um *Month 8 represents 6 months after first DURAVYU injection PRELIMINARY DATA – PENDING FINAL ANALYSIS Data from DAVIO 2 Suggests Strong Anatomic Cont
Slide 24: Sub-Group Analysis of Patients Anti-VEGF Supplement-Free Up to 6 Months
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 2 DAVIO 2 Trial in Wet AMD Sub-Group Analysis of Patients Anti-VEGF Supplement-Free Up to 6 Months
Slide 25: Numerical Superiority in BCVA in Supplement-Free Sub-Group
DURAVYU 2mg +0.6* Mean Change in BCVA vs Aflibercept DURAVYU 3mg +0.1* ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. +1.9* +2.4* +1.8* *Blended week 28 and week 32 change vs. baseline **Month 8 represents 6 months after DURAVYU injection PRELIMINARY DATA – PENDING FINAL ANALYSIS DURAVYU
Slide 26: Strong Anatomic Control in Supplement-Free Patients
DURAVYU 2mg +7.0 Mean Change in CST vs Aflibercept DURAVYU 3mg +0.6 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. +8.6 um +15.0 um +8.0 um *Month 8 represents 6 months after first DURAVYU injection PRELIMINARY DATA – PENDING FINAL ANALYSIS Strong Anatomic Control in Patients Supplement F
Slide 27: Phase 3 Pivotal Trials Design
s ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Phase 3 Pivotal Trials Design* NON-INFERIORITY VERSUS AN AFLIBERCEPT CONTROL *Pending final FDA review.
Slide 28: DURAVYU Non-Inferiority Phase 3 Clinical Trials Design in Wet AMD
DURAVYU Non-Inferiority Phase 3 Clinical Trials Design in Wet AMD ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Design of the Phase 3 trials were informed by previous Type C meeting with FDA and positive DAVIO 2 data with additional considerations for potential FDA approval and product l
Slide 29: Phase 2 VERONA Clinical Trial in Diabetic Macular Edema (DME)
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DURAVYU: vorolanib in Durasert E™ Phase 2 VERONA clinical trial IN Diabetic Macular Edema (DME)
Slide 30: VERONA: Randomized, Open-Label, Aflibercept Controlled Trial
Phase 2 VERONA Clinical Trial is a Randomized, Open-Label, Aflibercept Controlled Trial with a Single DURAVYU Injection DURAVYU dosing Visit Scheduled aflibercept injection Sham injection DURAVYU low dose (n=10) DURAVYU high dose (n=10) Aflibercept 2mg single injection (n=5) Supplemental Anti-VEGF i
Slide 31: VERONA Primary Endpoint: Time to Supplemental Injection
VERONA Primary Endpoint: Time to Supplemental Injection up to Week 24 – Supplement Criteria ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. vs. best on study measurement; 2. as measured by Spectral domain OCT (SD-OCT) BCVA, best corrected visual acuity; CST, central subfield thickness S
Slide 32: EYP-2301: razuprotafib in Durasert E
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. EYP-2301: razuprotafib in Durasert E™ A sustained delivery tie-2 agonist for severe retinal diseases
Slide 33: EYP-2301 Being Developed as Sustained Delivery Treatment for Serious Retinal Diseases
EYP-2301: Razuprotafib in Durasert E™ is Being Developed as a Sustained Delivery Treatment for Serious Retinal Diseases ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. Heier et al. Retina, 2021;41:1-19. and Joussen et al. Eye 2021; 35:1305-1316.; 2. Hammes, et. Al – Diabetes.2011 Jan 1;
Slide 34: Strong Balance Sheet: Cash Runway Through 2026
©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Cash runway through topline data in 2026 of pivotal Phase 3 clinical trials for DURAVYU in wet AMD Strong Balance Sheet $299M of cash and investments on March 31, 2023 No debt
Slide 35: Continued Execution And Well-Funded Through Key DURAVYU Milestones
Continued Execution And Well-Funded Through Key DURAVYU Milestones ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *EOP2, End of Phase 2; wet AMD, wet age-related macular degeneration; SAB, Scientific Advisory Board DURAVYU™ Corporate ✓ VERONA - DME Phase 2 Trial initiation Q1 2024 ✓ FDA c
Slide 36: Investor Presentation May 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.
Investor Presentation May 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved.